Press release
Osteoporosis Pipeline Drugs Analysis Report, 2024 Updates: FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight | Pfizer Inc., Eli Lilly and Company, F. Hoffmann La Roche, Merck & Co.
The Osteoporosis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
"Osteoporosis Pipeline Insight, 2024 [https://www.delveinsight.com/sample-request/osteoporosis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Osteoporosis Market.
Some of the key takeaways from the Osteoporosis Pipeline Report:
* Companies across the globe are diligently working toward developing novel Osteoporosis treatment therapies with a considerable amount of success over the years.
* Osteoporosis companies working in the treatment market are Lactocore, Rani Therapeutics, Jiangsu HengRui Medicine, Entera Bio, Levolta Pharmaceuticals, Inc., Celltrion, Teva Pharmaceuticals, and others, are developing therapies for the Osteoporosis treatment
* Emerging Osteoporosis therapies in the different phases of clinical trials are- Research programme, RT-102, SHR-1222, EB613, VOLT01, CT-P41, TVB-009, and others are expected to have a significant impact on the Osteoporosis market in the coming years.
* In March 2024, Sandoz produced Jubbonti (denosumab-bbdz), which is an interchangeable biosimilar to Prolia (denosumab), functioning as a RANK ligand (RANKL) inhibitor for treating osteoporosis.
* In March 2023, Teva Pharmaceuticals commenced a randomized, double-blind, multinational, multicenter study aimed at comparing the efficacy, safety, and immunogenicity of TVB-009P and Denosumab (Prolia Registered ) in individuals with postmenopausal osteoporosis. The primary objective of this study is to establish the similarity in efficacy and safety profiles between TVB-009 and Prolia (denosumab). This comprehensive, multinational, multicenter, randomized, double-blind investigation seeks to demonstrate comparable efficacy and safety of TVB-009 when compared to Prolia, both administered subcutaneously at doses of 60 mg every 26 weeks. The study will enroll approximately 326 postmenopausal women diagnosed with osteoporosis, randomizing them to receive either TVB-009 or Prolia.
Osteoporosis Overview
Osteoporosis is a medical condition characterized by the weakening of bones, making them fragile and more susceptible to fractures. It occurs when the density and quality of bone are reduced. Bones naturally undergo a process of remodeling, where old bone tissue is replaced by new bone tissue. In osteoporosis, this balance is disrupted, leading to a decrease in bone density and an increased risk of fractures, typically in the hip, spine, and wrist.
Get a Free Sample PDF Report to know more about Osteoporosis Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/osteoporosis-pipeline-insight [https://www.delveinsight.com/report-store/osteoporosis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Emerging Osteoporosis Drugs Under Different Phases of Clinical Development Include:
* Research programme: Lactocore
* RT-102: Rani Therapeutics
* SHR-1222: Jiangsu HengRui Medicine
* EB613: Entera Bio
* VOLT01: Levolta Pharmaceuticals, Inc.
* CT-P41: Celltrion
* TVB-009: Teva Pharmaceuticals
Osteoporosis Route of Administration
Osteoporosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
* Intra-articular
* Intraocular
* Intrathecal
* Intravenous
* Ophthalmic
* Oral
* Parenteral
* Subcutaneous
* Topical
* Transdermal
Osteoporosis Molecule Type
Osteoporosis Products have been categorized under various Molecule types, such as
* Oligonucleotide
* Peptide
* Small molecule
Osteoporosis Pipeline Therapeutics Assessment
* Osteoporosis Assessment by Product Type
* Osteoporosis By Stage and Product Type
* Osteoporosis Assessment by Route of Administration
* Osteoporosis By Stage and Route of Administration
* Osteoporosis Assessment by Molecule Type
* Osteoporosis by Stage and Molecule Type
DelveInsight's Osteoporosis Report covers around 40+ products under different phases of clinical development like
* Late-stage products (Phase III)
* Mid-stage products (Phase II)
* Early-stage product (Phase I)
* Pre-clinical and Discovery stage candidates
* Discontinued & Inactive candidates
* Route of Administration
Further Osteoporosis product details are provided in the report. Download the Osteoporosis pipeline report to learn more about the emerging Osteoporosis therapies [https://www.delveinsight.com/sample-request/osteoporosis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Some of the key companies in the Osteoporosis Therapeutics Market include:
Key companies developing therapies for Osteoporosis are - Pfizer Inc., Eli Lily and Company, F. Hoffmann La Roche, Merck & Co. Inc., Amgen Inc., Radius Health Inc., Teva Pharmaceutical Industries Ltd, GlaxoSmithKline PLC, Novartis International AG, Actavis PLC, and others.
Osteoporosis Pipeline Analysis:
The Osteoporosis pipeline report provides insights into
* The report provides detailed insights about companies that are developing therapies for the treatment of Osteoporosis with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Osteoporosis Treatment.
* Osteoporosis key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Osteoporosis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Osteoporosis market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Osteoporosis drugs and therapies [https://www.delveinsight.com/sample-request/osteoporosis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Osteoporosis Pipeline Market Drivers
* Rising geriatric population prone to low bone density, growing investments in research and development, increased Focus on development of biosimilars for the treatment of Osteoporosis are some of the important factors that are fueling the Osteoporosis Market.
Osteoporosis Pipeline Market Barriers
* However, side effects and complications associated with osteoporosis drugs, patent expiration of osteoporosis drugs and other factors are creating obstacles in the Osteoporosis Market growth.
Scope of Osteoporosis Pipeline Drug Insight
* Coverage: Global
* Key Osteoporosis Companies: Lactocore, Rani Therapeutics, Jiangsu HengRui Medicine, Entera Bio, Levolta Pharmaceuticals, Inc., Celltrion, Teva Pharmaceuticals, and others
* Key Osteoporosis Therapies: Research programme, RT-102, SHR-1222, EB613, VOLT01, CT-P41, TVB-009, and others
* Osteoporosis Therapeutic Assessment: Osteoporosis current marketed and Osteoporosis emerging therapies
* Osteoporosis Market Dynamics: Osteoporosis market drivers and Osteoporosis market barriers
Request for Sample PDF Report for Osteoporosis Pipeline Assessment and clinical trials [https://www.delveinsight.com/sample-request/osteoporosis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Table of Contents
1. Osteoporosis Report Introduction
2. Osteoporosis Executive Summary
3. Osteoporosis Overview
4. Osteoporosis- Analytical Perspective In-depth Commercial Assessment
5. Osteoporosis Pipeline Therapeutics
6. Osteoporosis Late Stage Products (Phase II/III)
7. Osteoporosis Mid Stage Products (Phase II)
8. Osteoporosis Early Stage Products (Phase I)
9. Osteoporosis Preclinical Stage Products
10. Osteoporosis Therapeutics Assessment
11. Osteoporosis Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Osteoporosis Key Companies
14. Osteoporosis Key Products
15. Osteoporosis Unmet Needs
16 . Osteoporosis Market Drivers and Barriers
17. Osteoporosis Future Perspectives and Conclusion
18. Osteoporosis Analyst Views
19. Appendix
20. About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=osteoporosis-pipeline-drugs-analysis-report-2024-updates-fda-approvals-clinical-trials-therapies-moa-roa-by-delveinsight-pfizer-inc-eli-lilly-and-company-f-hoffmann-la-roche-merck-co]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Osteoporosis Pipeline Drugs Analysis Report, 2024 Updates: FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight | Pfizer Inc., Eli Lilly and Company, F. Hoffmann La Roche, Merck & Co. here
News-ID: 3449613 • Views: …
More Releases from ABNewswire
Understanding Magnetic Switches: Types, Working Principles, and Applications
A magnetic switch is a versatile electrical device that operates by responding to magnetic fields. From Hall Effect to reed switches, explore their functions, types, and diverse applications.
What is a Magnetic Switch?
A magnetic switch is an electrical device that operates by responding to the presence of a magnetic field. It functions by closing or opening its contacts based on the strength of the magnetic field. Specifically, the switch remains closed…
Innovating embedded downlight technology: Leading the global trend of intelligen …
The strong rise of China's manufacturing industry has profoundly reshaped the technological landscape and development trajectory of embedded downlights. With its unparalleled industrial chain advantages, continuous technological innovation, and significant cost-effectiveness, Chinese enterprises have risen from participants in the global lighting industry to undisputed leaders. This transformation goes far beyond the huge production scale; it lies in the thorough innovation of the core technical content and application boundaries of embedded…
North China Electric Power University Foreign Aid Training Program Visits Yiyuan …
On July 23, 2025, the Electrical Industry Training Program of North China Electric Power University's Foreign Aid Project visited Yiyuan Technology for an exchange visit. The purpose was to gain in-depth insights into the company's innovations in renewable energy technology promotion and application [https://www.yiyen.com/about/], and to build bridges connecting university-enterprise cooperation with foreign aid initiatives.
Image: https://ecdn6.globalso.com/upload/p/1108/image_other/2025-07/scene-1.jpg
Image: https://ecdn6.globalso.com/upload/p/1108/image_other/2025-07/scene-3.jpg
Upon arrival, the delegation received a warm welcome from company leadership and the reception…
Pure Sine Wave Low Frequency Inverter Charger
Pure sine wave low frequency inverter [https://www.yiypower.com/ap-mini-600w-1500w-120v-low-frequency-pure-sine-wave-inverter-charger-product/] is widely used and suitable for a variety of scenarios. In terms of home backup power, it can provide reliable power during power outages, ensuring that essential appliances such as refrigerators, air conditioners and medical equipment continue to operate . For solar power generation systems, Inverter charger [https://www.yiypower.com/ap-mini-600w-1500w-120v-low-frequency-pure-sine-wave-inverter-charger-product/] can converter DC Power from Battery, which charged by solar panels, into clean alternating current…
More Releases for Osteoporosis
Rising Prevalence Of Osteoporosis Fuels Growth In The Osteoporosis Drug Market: …
The Osteoporosis Drugs Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the Expected Osteoporosis Drugs Market Size During the Forecast Period?
The market for medications for osteoporosis has seen a consistent rise in recent years. The current market value of $12.33 billion in 2024…
Rising Prevalence Of Osteoporosis Spurs Momentum In Postmenopausal Osteoporosis …
The Postmenopausal Osteoporosis Treatment Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the Current Postmenopausal Osteoporosis Treatment Market Size and Its Estimated Growth Rate?
The market for treatment of postmenopausal osteoporosis has seen a steady increase in size over the recent years. It's projected…
Osteoporosis Drug Market, By Type (Primary Osteoporosis and Secondary Osteoporos …
Osteoporosis is a condition of bone weakening or bones becomes fragile and likely to break. In other words, osteoporosis is a condition wherein the bone density decreases. This is specially witnessed in old age people. Osteoporosis brings along back pain, stooped posture, bone fracture and tooth loss.
View Detailed Report" https://www.databridgemarketresearch.com/reports/global-osteoporosis-drug-market
The global osteoporosis drug market is experiencing steady growth driven by factors such as the increasing aging population, rising prevalence of…
Osteoporosis Drugs: The Complete Review
Medication for osteoporosis increases bone mineral density and reduces fracture risk. Some osteoporosis medications promote bone growth while others reduce bone loss.
The bones may begin to deteriorate as age more quickly than the body can heal them. The doctor could determine that people have osteoporosis if they have significant bone density loss.
To receive free sample pages of this report@ https://www.psmarketresearch.com/market-analysis/osteoporosis-drugs-market/report-sample
Although osteoporosis cannot be treated, it can be slowed down or…
Osteoporosis Drugs Market: Demand for Osteoporosis Drugs High Among Geriatric Po …
The global osteoporosis drugs market is analyzed in a report by Transparency Market Research (TMR). The market is expected to grow due to the increasing geriatric population across the globe. The market for osteoporosis drugs is considered semi-consolidated as a handful of players hold a larger share in the market. As per the analysis, Novartis International AG, Eli Lilly and Company, Merck & Co. Inc., Pfizer Inc., and Amgen Inc.…
Global Postmenopausal Osteoporosis Therapeutics Market
The Postmenopausal Osteoporosis Therapeutics Market report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.
Osteoporosis is an orthopedic condition where the bone density and bone mass decreases and eventually increases the risk of bone fracture. Osteoporosis is one of the most common age related…
